Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

Ramzi Abboud; Ezhilarasi Chendamarai; Michael P. Rettig; Kathryn M. Trinkaus; Peter A. Riedell; Camille N. Abboud; Armin Ghobadi; Iskra Pusic; Keith Stockerl-Goldstein; Mark A. Schroeder; Ravi Vij; Peter Westervelt; John F. DiPersio; Geoffrey L. Uy

doi:10.3324/haematol.2019.236810

Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

Ramzi Abboud, Ezhilarasi Chendamarai, Michael P. Rettig, Kathryn M. Trinkaus, Peter A. Riedell, Camille N. Abboud, Armin Ghobadi, Iskra Pusic, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Peter Westervelt, John F. DiPersio, Geoffrey L. Uy

Research output: Contribution to journal › Letter › peer-review

9 Scopus citations

Original language	English
Pages (from-to)	E404-E407
Journal	Haematologica
Volume	105
Issue number	8
DOIs	https://doi.org/10.3324/haematol.2019.236810
State	Published - Aug 1 2020

Access to Document

10.3324/haematol.2019.236810

Cite this

Abboud, R., Chendamarai, E., Rettig, M. P., Trinkaus, K. M., Riedell, P. A., Abboud, C. N., Ghobadi, A., Pusic, I., Stockerl-Goldstein, K., Schroeder, M. A., Vij, R., Westervelt, P., DiPersio, J. F., & Uy, G. L. (2020). Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica, 105(8), E404-E407. https://doi.org/10.3324/haematol.2019.236810

@article{33bd82b26c9c4dd8ab1b076435889d20,

title = "Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia",

author = "Ramzi Abboud and Ezhilarasi Chendamarai and Rettig, {Michael P.} and Trinkaus, {Kathryn M.} and Riedell, {Peter A.} and Abboud, {Camille N.} and Armin Ghobadi and Iskra Pusic and Keith Stockerl-Goldstein and Schroeder, {Mark A.} and Ravi Vij and Peter Westervelt and DiPersio, {John F.} and Uy, {Geoffrey L.}",

note = "Funding Information: 1Division of Oncology, Washington University School of Medicine and 2Biostatistics Shared Resource Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA °Current Address: Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA Funding: The Alvin J. Siteman Cancer Center is supported in part by National Cancer Institute Cancer Center Support grant P30 CA91842. RA is supported by the American Society of Hematology Clinical Research Training Institute and the National Cancer Institute of the National Institutes of Health under Award Number R25 CA190190. Correspondence: GEOFFREY L. UY - guy@wustl.edu doi:10.3324/haematol.2019.236810 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.",

year = "2020",

month = aug,

day = "1",

doi = "10.3324/haematol.2019.236810",

language = "English",

volume = "105",

pages = "E404--E407",

journal = "Haematologica",

issn = "0390-6078",

number = "8",

}

Abboud, R, Chendamarai, E, Rettig, MP, Trinkaus, KM, Riedell, PA, Abboud, CN , Ghobadi, A , Pusic, I , Stockerl-Goldstein, K , Schroeder, MA , Vij, R , Westervelt, P , DiPersio, JF & Uy, GL 2020, 'Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia', Haematologica, vol. 105, no. 8, pp. E404-E407. https://doi.org/10.3324/haematol.2019.236810

TY - JOUR

T1 - Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

AU - Abboud, Ramzi

AU - Chendamarai, Ezhilarasi

AU - Rettig, Michael P.

AU - Trinkaus, Kathryn M.

AU - Riedell, Peter A.

AU - Abboud, Camille N.

AU - Ghobadi, Armin

AU - Pusic, Iskra

AU - Stockerl-Goldstein, Keith

AU - Schroeder, Mark A.

AU - Vij, Ravi

AU - Westervelt, Peter

AU - DiPersio, John F.

AU - Uy, Geoffrey L.

N1 - Funding Information: 1Division of Oncology, Washington University School of Medicine and 2Biostatistics Shared Resource Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA °Current Address: Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA Funding: The Alvin J. Siteman Cancer Center is supported in part by National Cancer Institute Cancer Center Support grant P30 CA91842. RA is supported by the American Society of Hematology Clinical Research Training Institute and the National Cancer Institute of the National Institutes of Health under Award Number R25 CA190190. Correspondence: GEOFFREY L. UY - guy@wustl.edu doi:10.3324/haematol.2019.236810 Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

PY - 2020/8/1

Y1 - 2020/8/1

UR - http://www.scopus.com/inward/record.url?scp=85086936701&partnerID=8YFLogxK

U2 - 10.3324/haematol.2019.236810

DO - 10.3324/haematol.2019.236810

M3 - Letter

C2 - 31753931

AN - SCOPUS:85086936701

SN - 0390-6078

VL - 105

SP - E404-E407

JO - Haematologica

JF - Haematologica

IS - 8

ER -

Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

Access to Document

Other files and links

Cite this